BKM120 For Triple Negative Breast Cancer
NCT01790932
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
BKM120
Sponsor
Dana-Farber Cancer Institute